Maria Carmela Leo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Carmela Leo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Barucci
Istituto di Fisica Applicata “Nello Carrara”, Sesto Fiorentino, Italy
1 shared publication - Antonio Marzola
University of L’Aquila
1 shared publication Carolina Sforzi
Meyer Children's Hospital
1 shared publication- Ilaria Romagnuolo
Azienda Ospedaliero-Universitaria Careggi
1 shared publication - Martina Falconi
Meyer Children's Hospital
1 shared publication - Roberto Pini
Istituto di Fisica Applicata “Nello Carrara”, Consiglio Nazionale delle Ricerche (CNR-IFAC), 50019 Florence, Italy
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 14 January 2026
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 21
Ethical and Regulatory Frameworks for Artificial Intelligence in Clinical Research: A European Perspective on the Artificial Intelligence Act for Ethics Committees and Researchers
The rapid integration of artificial intelligence (AI) into clinical research is transforming the landscape of biomedical innovation, influencing numerous phases of research, with critical ethical and legal implications. Regulation (EU) 2024/1689, commonly referred to as the AI Act and issued in 2024, introduced a new regulatory framework that classifies AI systems used in clinical settings as ‘high risk’, requiring increased scrutiny by ethics committees and national authorities. This review addresses ethical and regulatory challenges and discusses the application of the AI Act within real-world clinical research. We propose a three-phase lifecycle (training, real-world testing and post-marketing monitoring) to align regulatory burdens with AI maturity. Our recommendations include transparent protocol design with explicit data-use declarations, complementary application of the Medical Device Regulation and the AI Act, with particular attention to the early research phases. This approach provides practical indications for researchers and operational evaluation criteria for ethics committees to ensure patient safety while fostering trustworthy AI deployment in clinical trials.
- 14 January 2026
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 21
Top Cited PapersOpen AccessEthical and Regulatory Frameworks for Artificial Intelligence in Clinical Research: A European Perspective on the Artificial Intelligence Act for Ethics Committees and Researchers
The rapid integration of artificial intelligence (AI) into clinical research is transforming the landscape of biomedical innovation, influencing numerous phases of research, with critical ethical and legal implications. Regulation (EU) 2024/1689, commonly referred to as the AI Act and issued in 2024, introduced a new regulatory framework that classifies AI systems used in clinical settings as ‘high risk’, requiring increased scrutiny by ethics committees and national authorities. This review addresses ethical and regulatory challenges and discusses the application of the AI Act within real-world clinical research. We propose a three-phase lifecycle (training, real-world testing and post-marketing monitoring) to align regulatory burdens with AI maturity. Our recommendations include transparent protocol design with explicit data-use declarations, complementary application of the Medical Device Regulation and the AI Act, with particular attention to the early research phases. This approach provides practical indications for researchers and operational evaluation criteria for ethics committees to ensure patient safety while fostering trustworthy AI deployment in clinical trials.